Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
JPM 2021
Biotech
Beyond COVID-19, where will biopharma focus in 2021?
We asked executives which areas might see a resurgence this year and neurology emerged as a popular horse to bet on.
Amirah Al Idrus
Jan 22, 2021 11:00am
JPM: Thermo Fisher picks up Novasep's viral vector arm for $878M
Jan 15, 2021 10:04am
Can we take JPM out of San Francisco? We're virtually there
Jan 14, 2021 10:26am
Biotechs on what an aducanumab nod could mean for Alzheimer’s
Jan 13, 2021 11:24am
JPM: Imara CEO on fighting sickle cell disease during COVID-19
Jan 13, 2021 10:25am
JPM, Day 3: CureVac partner Bayer says not to discount its vax
Jan 13, 2021 10:05am
